Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 16/20 | 0.61 |
| ▸ | FGFR4 | P22455 | 12/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30212046 | 1.00 | FGFR1 (0.61) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL22321423 | 0.88 | FGFR4 (0.58) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL22321438 | 0.87 | FGFR1 (0.59) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL30212015 | 0.87 | FGFR1 (0.59) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL20330520 | 0.84 | FGFR1 (0.65) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL30044812 | 0.84 | FGFR1 (0.65) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL22343097 | 0.83 | FGFR1 (0.60) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL22321481 | 0.83 | FGFR1 (0.60) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL30212068 | 0.83 | FGFR1 (0.60) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL22321463 | 0.81 | FGFR1 (0.60) | FGFR1FGFR4FGFR2FGFR3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278823-B | Heterocyclic compounds as fibroblast growth factor receptor inhibitors | 上海新契博生物科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20200253978-A1 | HETEROCYCLICS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | ADVNET PHARMA CO. LTD. (CN) | 2020-08-13 | — | — | US | disclosed |
| US-20200253978-A1 | HETEROCYCLICS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | ADVNET PHARMA CO. LTD. (CN) | 2020-08-13 | — | — | US | disclosed |
| CN-111278823-A | Heterocyclic compounds as fibroblast growth factor receptor inhibitors | 上海新契博生物科技有限公司 | 2020-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253978-A1 | HETEROCYCLICS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR4, FGFR2 | FGFR1 1/4885FGFR4 2/4885FGFR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.